Ask about this productRelated genes to: BMP6 antibody
- Gene:
- BMP6 NIH gene
- Name:
- bone morphogenetic protein 6
- Previous symbol:
- VGR
- Synonyms:
- VGR1
- Chromosome:
- 6p24.3
- Locus Type:
- gene with protein product
- Date approved:
- 1991-06-05
- Date modifiied:
- 2016-10-05
Related products to: BMP6 antibody
Related articles to: BMP6 antibody
- Lmx1a/b paralogous genes, which arose from the invertebrate Lmx1b-like gene, are critical for hearing in multiple vertebrate species, and mutations in these genes cause hearing deficits in humans. While the unique and redundant functions of Lmx1a/b in the inner ear are well established, their contribution to the development of the cochlear nuclei, which process and relay auditory information to the brain, is poorly understood. Since cochlear nuclei maturate postnatally, here we analyzed Lmx1a;Lmx1b, Lmx1a, and Lmx1a;Lmx1b mice that survive past birth. Loss of Lmx1a reduced distinct populations of excitatory neurons in dorsal (DCN) and ventral (VCN) cochlear nuclei and their innervation from the inner ear. Additional loss of one Lmx1b copy made Lmx1a phenotypes more severe, revealing that Lmx1b acts redundantly with Lmx1a. Unlike Lmx1a mice, excitatory neurons were not affected in Lmx1a;Lmx1b mice. Thus, while cochlear nuclei are sensitive to Lmx1a/b gene dosage, these genes are not completely equivalent, and Lmx1a has a more profound role in cochlear nuclei development. Lmx1a and especially Lmx1a;Lmx1b embryos had fewer Atoh1+ progenitors that produce excitatory neurons of the cochlear nuclei, and reduced Bmp6 expression in the roof plate, the signaling center that induces these progenitors via Bmp signaling. We found that Lmx1a is the primary regulator of Bmp6, whereas Lmx1b contributes only in the absence of Lmx1a. Thus, Lmx1a plays a major role in the formation of the mature structure and connectivity of both the DCV and VCN, and Lmx1b acts redundantly to Lmx1a but only partially compensates for Lmx1a loss. - Source: PubMed
Publication date: 2026/04/17
Iskusnykh Igor YFritzsch BerndYamoah Ebenezer NSteshina Ekaterina YChizhikov Victor V - About 20-40% of prostate cancer (PCa) develop biochemical recurrence (BCR) after surgery, and propionate metabolism may contribute to tumor progression. BCR remains a major clinical challenge in PCa, as current tools based on histopathology and prostate-specific antigen (PSA) fail to capture the molecular heterogeneity driving the disease. While metabolic reprogramming is known to facilitate post-treatment adaptation, the specific role of propionate metabolism in this context remains largely unexplored. Therefore, this study aimed to systematically investigate propionate metabolism-related genes (PMRGs) to develop a novel prognostic model for the improved early prediction of recurrence. - Source: PubMed
Publication date: 2026/03/10
Lu BaosaiNiu YalinLiu XiZhao ChenmingYin Yuewei - Intervertebral disc degeneration (IVDD) is a prevalent condition causing substantial pain, muscle weakness, and functional impairment; however, the efficacy of current treatments remains limited. Therefore, candidate therapeutic targets must urgently be prioritized to guide future mechanistic and translational research. This study aims to identify genetic factors associated with IVDD and explore the underlying mechanisms through the comprehensive integration of multi-omics data. - Source: PubMed
Publication date: 2026/03/14
Kan ShunliLiu WentaoLi PeishengZhou MengmengYu HaoZheng YuwenHu WeiZhu Rusen - Fibrinogen-like protein 1 (FGL1) has been recently identified as an emerging novel checkpoint ligand of lymphocyte activation gene-3 (LAG-3) with important immunoregulatory functions. In addition to LAG-3, FGL1 also interacts with bone morphogenetic protein 6 (BMP6), activin receptor-like kinase 5 (ALK5) and other unidentified receptors to perform biological functions. Physiologically, FGL1 restrains intrahepatic immunity and preserves tolerance. Pathologically, FGL1 is frequently upregulated in various tumors and autoimmune diseases and is closely related to the occurrence and development of these diseases. Targeting FGL1 has shown preclinical efficacy in enhancing immunotherapy involving programmed death ligand 1 (PD-L1)/PD-1 checkpoint blockade, inhibiting liver metastasis and relieving autoimmunity without overt hepatotoxicity. In this review, we summarize recent advances in FGL1, focus on the immunoregulatory functions of FGL1, and evaluate its potential as a therapeutic target for immune-related diseases. - Source: PubMed
Publication date: 2026/02/18
Xi FengjiaLiu Rongzeng - Metastatic osteolytic bone tumors represent a clinical challenge as their pathogenesis and progression involve complex interactions within the bone microenvironment. Sclerostin, a key inhibitor of the Wnt signaling pathway, is critical to bone metabolism; however, its involvement in metastatic bone tumors remains insufficiently characterized. This study investigated sclerostin's role in metastatic osteolytic tumors, specifically its relationship with other bone remodeling molecules, including DKK1, BMP6, and the proliferation marker Ki67. - Source: PubMed
Hashimoto KazuhikoNishimrua ShunjiTan HirokiIto TomohikoGoto Koji